Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company's business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine). The Company focuses its research and development on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience. Its products in Phase III programs include Aranesp for Myelodysplastic syndromes; ENBREL for Psoriatic arthritis and Rheumatoid arthritis remission; IMLYGIC for Metastatic melanoma, and Kyprolis for Multiple myeloma.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: AMGN
- CUSIP: 03116210
- Previous Close: $174.01
- 50 Day Moving Average: $161.49
- 200 Day Moving Average: $159.22
- 52-Week Range: $133.64 - $176.85
- Trailing P/E Ratio: 16.99
- Foreward P/E Ratio: 13.61
- P/E Growth: 2.08
- Market Cap: $128.15B
- Outstanding Shares: 736,452,000
- Beta: 1.15
- Net Margins: 33.59%
- Return on Equity: 29.42%
- Return on Assets: 11.47%
Companies Related to Amgen:
- Debt-to-Equity Ratio: 1.01%
- Current Ratio: 4.11%
- Quick Ratio: 3.86%
What is Amgen's stock symbol?
Amgen trades on the NASDAQ under the ticker symbol "AMGN."
How often does Amgen pay dividends? What is the dividend yield for Amgen?
Amgen announced a quarterly dividend on Tuesday, December 20th. Investors of record on Wednesday, February 15th will be given a dividend of $1.15 per share on Wednesday, March 8th. This represents a $4.60 annualized dividend and a dividend yield of 2.64%. The ex-dividend date is Monday, February 13th. This is a positive change from Amgen's previous quarterly dividend of $1.00.
Where is Amgen's stock going? Where will Amgen's stock price be in 2017?
22 brokers have issued 12-month price objectives for Amgen's shares. Their forecasts range from $161.00 to $218.00. On average, they expect Amgen's share price to reach $184.89 in the next year.
When will Amgen announce their earnings?
Amgen is scheduled to release their next quarterly earnings announcement on Wednesday, April, 26th 2017.
What are analysts saying about Amgen stock?
Here are some recent quotes from research analysts about Amgen stock:
- BMO Capital Markets analysts commented, "Addition of CV outcomes data to the Repatha label and launch of erenumab for migraine (both in 2018) could enable Amgen to grow revenues in the face of a declining legacy business. This combined with margin expansion supports upward revision to our earnings estimates and a higher price target of $202 (vs. $197). We expect presentation of the FOURIER outcomes data at the ACC conference on March 17 to meet payor criteria for a 20% improvement in MACE and support opening of access, driving our $5B peak sales estimate." (2/3/2017)
- Cann analysts commented, "We now estimate Amgen's revenue will grow at a compound annual rate of 2.5% for the next four years, with diluted GAAP EPS growth of 8.5% per year. Based on our increased earnings estimates, we are raising our target price to $175 from our previous target price of $166." (2/3/2017)
According to Zacks Investment Research, "Amgen growth products – Prolia, Xgeva, Vectibix, Nplate and Sensipar – are performing well. Amgen’s restructuring plan should make it leaner and more cost efficient. Amgen is also progressing with its pipeline given quite a few regulatory and data updates scheduled for the coming quarters. Amgen has a positive record of earnings surprises in recent quarters. Amgen’s shares surpassed that of Biomed-Genetics industry in 2016. However, the company has some challenges in store given the presence of biosimilar competition and slowdown in sales of mature products. Biosimilars are starting to have a negative impact on key products like Neupogen and Neulasta in the EU. Moreover, minimal sales price increases and stiff competition can hurt blockbuster Enbrel sales in 2017. Estimates have also declined lately ahead of the company’s Q4 earnings release." (1/3/2017)
Jefferies Group LLC analysts commented, "Impella secured approval in Japan; the late summer approval was largely on target. The label is somewhat different than in the US: Impella is indicated for drug-resistant acute heart failure, but not prophylactic or elective use." (9/28/2016)
Credit Suisse Group analysts commented, "We remain focused on the two AMG 334 episodic migraine Ph3 readouts, ABP- 501 potential approval, full Ph3 FRAME results of Romosozumab and Kyprolis Clarion data in the 2H 2016." (7/28/2016)
Who owns Amgen stock?
Amgen's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (5.48%), State Street Corp (4.61%), Franklin Resources Inc. (1.12%), Janus Capital Management LLC (0.94%), Loomis Sayles & Co. L P (0.41%) and Orbimed Advisors LLC (0.32%). Company insiders that own Amgen stock include Annette Louise Such, Carbonnel Francois De, Cynthia M Patton, David Baltimore, Fred Hassan, Madhavan Balachandran, Sean E Harper and Stuart A Tross.
Who sold Amgen stock? Who is selling Amgen stock?
Amgen's stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Thrivent Financial for Lutherans, Renaissance Technologies LLC, Orbimed Advisors LLC, Artemis Investment Management LLP, AMF Pensionsforsakring AB, Credit Agricole S A and Fiera Capital Corp. Company insiders that have sold Amgen stock in the last year include Annette Louise Such, David Baltimore, Madhavan Balachandran and Sean E Harper.
Who bought Amgen stock? Who is buying Amgen stock?
Amgen's stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main, Asset Management One Co. Ltd., State Street Corp, Russell Investments Group Ltd., FIL Ltd, I.G. Investment Management LTD. and Prudential PLC.
How do I buy Amgen stock?
Shares of Amgen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Amgen stock cost?
One share of Amgen stock can currently be purchased for approximately $174.56.